CROI 2022: Advances in Antiviral Therapy for HIV, COVID-19, and Viral Hepatitis

Shauna H. Gunaratne, Hong Van Tieu, Timothy J. Wilkin, Barbara S. Taylor

Research output: Contribution to journalReview articlepeer-review


The 2022 Conference on Retroviruses and Opportunistic Infections provided a rich source of new data and comprehensive reviews on antiviral therapy. For COVID-19, intramuscular sotrovimab was noninferior to intravenous sotrovimab, serostatus did not predict the efficacy of sotrovimab, and molnupiravir appeared safe and modestly effective in decreasing hospitalization rates. Trials from low- and middle-income countries provided data to support transitioning those on first-line therapy with or without virologic suppression and those virologically suppressed on second-line therapy to dolutegravir-based regimens. Additional data supported the use of lenacapavir as a long-acting antiretroviral drug. Data across the United States demonstrate the negative impact of the COVID-19 pandemic on the HIV care continuum, although enhanced outreach efforts and decentralization of antiretroviral therapy delivery were associated with improvements in care engagement outcomes. Researchers described potential mechanisms for the emergence of integrase strand transfer inhibitor resistance. Studies on proviral genotyping highlighted the limitations of its use in predicting clinically significant resistance. Several studies looked at the epidemiology and treatment of hepatitis C and B and the status of current hepatitis C virus elimination efforts. Data presented on HIV, COVID-19, and maternal and pediatric health included 2-year virologic outcome data of very early antiretroviral therapy in potentially reducing the latent HIV reservoir in infants with HIV. Data presented on COVID-19 and HIV therapeutics in children included SARS-CoV-2-neutralizing monoclonal antibodies in children younger than 12 years of age, remdesivir in hospitalized infants and children, and long-acting therapies for HIV treatment in children.

Original languageEnglish (US)
Pages (from-to)490-521
Number of pages32
JournalTopics in Antiviral Medicine
Issue number3
StatePublished - Jun 1 2022


  • COVID-19
  • HIV
  • SARS-CoV-2
  • healthcare delivery
  • hepatitis
  • hepatitis B
  • hepatitis C
  • lenacapavir
  • sotrovimab

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'CROI 2022: Advances in Antiviral Therapy for HIV, COVID-19, and Viral Hepatitis'. Together they form a unique fingerprint.

Cite this